Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bavarian Nordic A/S (OP: BVNKF )

41.92 +1.92 (+4.80%)
Streaming Delayed Price Updated: 3:11 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bavarian Nordic A/S

Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency
Bavarian Nordic submits data to European Medicines Agency seeking approval to extend Imvanex vaccine use to adolescents. New trials in younger children planned as global demand for smallpox and mpox... 
Via Benzinga
Monkeypox Vaccine Maker Bavarian Nordic Bets $380M On Emergent Bio's Travel Vaccines
Via Benzinga
West Africa-Based Studies Show JNJ, Merck's Ebola Vaccines Provide Lasting Antibodies
Via Benzinga
Threats For New Outbreak Looms, As Scientists Signal Deadly Monkeypox Variant Circulating In Central Africa
Researchers have warned that a dangerous monkeypox variant with a fatality rate as high as 10% is circulating in Central Africa, which could trigger new global outbreaks. After analyzing 1,463 cases... 
Via Benzinga
Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine
Via Benzinga
Bavarian Nordic's Monkeypox Vaccine Gets Thumbs Up From EU Regulator
Via Benzinga
EU, Bavarian Nordic Ink Supply Pact For 110,000 Monkeypox Vaccines
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Is Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has Slowed
Via Benzinga
SIGA Tech Made The Smallpox Treatment As Post-9/11 Bioterrorism Defense: Report
In an effort to prevent bioterrorism attacks, just in case, SIGA Technologies Inc (NASDAQ: SIGA) started working on the smallpox treatment, Tpoxx, after the 9/11 terrorist attack that shook the world.... 
Via Benzinga
Bavarian Nordic Making All Efforts To Stretch Capacity To Boost Monkeypox Vaccine Supplies
Bavarian Nordic A/S (OTC: BVNRY) said it was making "every effort" to meet the high demand for its monkeypox vaccine worldwide as it kept its business outlook for the year. 
Via Benzinga
Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch
The only FDA-approved monkeypox vaccine from Bavarian Nordic A/S (OTC: BVNY) is in short supply. 
Via Benzinga
Applied DNA Seeks Approval For PCR-Based Monkeypox Virus Test
Via Benzinga
Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment
Top Biden administration officials are poised to lay out new steps to accelerate the U.S. response amid the spread of monkeypox and demand for vaccines & treatments. 
Via Benzinga
WeTrade Shares Soar On Collaboration Over Exclusive COVID-19 Omicron Disinfectant
Via Benzinga
A Biopharma Working On Malaria, Norovirus Vaccines Threw It's Hat In The Monkeypox Ring
Blue Water Vaccines Inc (NASDAQ: BWV)  
Via Benzinga
Benzinga Before The Bell: More Amazon Workers Join Union Over Pay and Work Conditions, UK Inflation Highest In 40 Years, Sole Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand And Other Top Financial Stories Wednesday, August 17
CNBC BlackRock To Pledge A$1B In Australian Battery Storage Assets – Report 
Via Benzinga
The Only Monkeypox Vaccine Maker Finds It Difficult To Meet Accelerating Demand
Bavarian Nordic A/S (OTC: BVNKF), the only company with an approved vaccine for monkeypox, said it’s no longer sure it can meet demand as cases continue to rise worldwide, 
Via Benzinga
Bavarian Nordic's Monkeypox Vaccine Scores EU Approval As WHO Declares Global Health Emergency
Via Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Bavarian Nordic Inks Multiple Supply Pact For Its Monkey pox Vaccine, Updates FY22 Guidance
Via Benzinga
Bavarian Nordic Launches COVID-19 Booster Study To Compare Against Pfizer/BioNTech Shot
Via Benzinga
This Famed Company Is Working On A Potential Monkeypox Vaccine
As cases of monkeypox continue to rise, Moderna Inc (NASDAQ: MRNA) is probably working on its platform towards finding a vaccine shot against the disease. 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.